FDA Approves Columvi (glofitamab-gxbm) Bispecific Antibody for the Treatment of Relapsed orRefractory Diffuse Large B-Cell Lymphoma
June 15, 2023FDA Approves Lodoco (colchicine) as the First Anti-Inflammatory Drug for Cardiovascular Disease
June 20, 2023June 20, 2023 - Halozyme Therapeutics, Inc. has announced that argenx received U.S. Food and Drug Administration (FDA) approval for Vyvgart® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Vyvgart® Hytrulo is a subcutaneous product combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as Vyvgart®, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology to facilitate subcutaneous delivery of biologics. The product is to be administered subcutaneously by a healthcare professional as a single injection (1,008 mg fixed dose) over 30-90 seconds in cycles of once weekly injections for four weeks.